Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Sep 1;6(1):96–112. doi: 10.36469/9791

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CCBY-4.0). View this license’s legal deed at http://creativecommons.org/licenses/by/4.0 and legal code at http://creativecommons.org/licenses/by/4.0/legalcode for more information.

PMC Copyright notice

Duration of Biologic Therapy in Patients with UC and CD in 1-year and 2-year Cohorts

Median duration (with interquartile range) of biologic therapy in patients with UC (A and B) and CD (C and D) in the 1-year (A, C) and 2-year follow-up (B, D) cohorts (ITT population). Mean value represented by black circle.

Note: natalizumab and ustekinumab are not currently approved for treating UC and are likely captured due to off-label prescription and/or the algorithm used to categorize patients with UC versus CD.

CD: Crohn’s disease; ITT: intention-to-treat; UC: ulcerative colitis